A Novel Drug Candidate for Alopecia Areata: An Anti-BTLA Modulator

Time: 12:10 pm
day: Day 2 AM - Track B


  • Detailing the mode of action for checkpoint inhibitor modulation in chronic inflammatory dermatological disease
  • Cataloguing the dermatological diseases to approach with checkpoint inhibitor modulation
  • Considering endpoints: pharmacodynamics, moving trials beyond 16 weeks (how to know if we have truly reset the immune system), and psycho/social aspects of a life-limiting disease